To define the immune biomarker landscape of thoracic and head and neck NUT carcinoma within a clinicopathologic and fusion-partner framework, highlighting its significance in guiding future research.
Key Findings:
The integrated dataset included 229 thoracic/head and neck cases with definitive fusion annotations, providing a robust basis for analysis.
Squamous lineage predominated (71.62%), with BRD4::NUTM1 significantly enriched in squamous lineage, indicating potential diagnostic markers.
PD-L1 was predominantly negative (76.92%), with high expression being uncommon (6.41%), suggesting limited immunotherapy options.
Tumors were uniformly MSS and generally low in TMB, indicating a need for alternative therapeutic strategies.
Interpretation:
The predominance of PD-L1 negativity and MSS/low-TMB features suggests a generally immunologically 'cold' phenotype in most reported tumors, which may limit the effectiveness of current immunotherapies.
Limitations:
The study relies on literature-derived data which may have inherent biases, potentially affecting the generalizability of the findings.
Limited sample sizes in some studies may affect the robustness of findings, necessitating caution in interpretation.
Conclusion:
The study provides a translational basis for rare-cancer immunobiology research and for the rational design of biomarker-integrated prospective studies, emphasizing the need for further investigation into therapeutic strategies.
